US Specialty Formulations Announces $15 Million Expansion to Modernize Biopharma Operations

Event information

- US Specialty Formulations (USSF) is expanding its Lehigh Valley biopharma facility with a $15M initiative, expected to be completed by the end of 2025. - The expansion will include new clean room suites and state-of-the-art automated packaging and product inspection equipment, increasing production capacity by more than 2.5 times. - This initiative is projected to boost the local economy by creating over 100 jobs and increasing revenue for the Greater Philadelphia region. - USSF continues to pioneer in the life sciences industry, offering various pharmaceutical solutions and successfully completing a Phase I clinical trial for its QYNDR oral vaccine platform.